Navigation Links
Clinical Study Demonstrates Superior Bioavailability of Jarrow's Proprietary QH-absorb Formula
Date:6/13/2009

QH-absorb® as demonstrated by a reduction in the mean oxidized Co-Q10 levels in the plasma from 12% to 7%.

Jarrow L. Rogovin, President of Jarrow Formulas®, described another astonishing finding of the study. "Not only did our QH-absorb® increase plasma Co-Q10 levels two to three times more than other QH formulas, it also decreased the percentage of plasma oxidized Co-Q10 by 45%. It significantly increased the antioxidant, QH2, form of ubiquinol in the body. That is incredibly exciting for people watching their heart health or blood sugar."

Jarrow Formulas®' QH-absorb® is a proprietary stabilized formula that offers improved bioavailability over standard Co-Q10 supplements (ubiquinone), and is able to deliver Co-Q10 in its native antioxidant-capable form at higher levels. While standard Co-Q10 (ubiquinone) supplements can be reduced to the antioxidant state in the body, this reduction can be less efficient in some individuals due to health status, age or genetics. Ubiquinol also has significantly superior bioavailability to ubiquinone as demonstrated in clinical trials.

QH-absorb®, like Q-absorb®, uses an all-natural proliposome delivery system to improve absorption. Jarrow Formulas®' Q-absorb® and QH-absorb® delivery systems have been validated in multiple trials to significantly improve Co-Q10 absorption over other Co-Q10 formulas. Jarrow Formulas®' ubiquinol is derived from Co-Q10 that is manufactured via a yeast-fermentation process and consists only of the natural trans configuration, the same as is biosynthesized by humans.

Jarrow Formulas®' ubiquinol is supplied by

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS
2. Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawal
3. Clinical Innovations Introduces New Circumcision Device
4. New Directions in Angioedema: A Focus on Etiologies and Clinical Approach
5. DaVita Study Demonstrates Clinical Application of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
6. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
7. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
8. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
9. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
10. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
11. Ross University School of Medicine Expands Clinical Rotations in Miami
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton Hershey ... Congress of Future Medical Leaders in Boston, Mass. The ... highest achieving high school students.” , “I’m excited to ... and learn better study habits,” said Omar. “The event ... can ask the surgeons questions.” , The goal is ...
(Date:5/22/2015)... PITTSBURGH, Pa (PRWEB) May 22, 2015 ... Network (AHN) today announced a new partnership to ... program for the region. The initiative includes a new ... BodyStage live demonstration theater, and a new traveling ... in the fall of 2015. , Designed to ...
(Date:5/22/2015)... 22, 2015 Coco Libre, the Official Coconut ... World Record at the 104th running of the race. On ... luge served 315 people in one hour—one person about every ... is so true to the heart of the Bay Area, ... ice luge to the finish line only made sense,” said ...
(Date:5/22/2015)... York, NY (PRWEB) May 22, 2015 Medivo, ... entitled “Positivity Rates and Genotype Results in ‘Baby Boomers’ ... Results from a Nationwide Lab Test Database” at Digestive Disease ... by Medivo’s Clinical Affairs and Analytics team members Carol Smyth, ... MD; and Andrea Parker, MSI, along with Nancy Reau, MD ...
(Date:5/22/2015)... 2015 Ticket Down is a reputable source ... NHL Eastern Conference Finals Tickets . All seating for ... in the ticket listing. , For the first time ... top of the Eastern Conference. One of the original franchises ... ups and downs over the years, but the excitement level ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... cause of 90 percent of the world’s lung cancer ... cigarettes they smoke per day are exposed to lower ... However, the reduction in the amount or concentration of ... to the reduction in cigarettes smoked. ,Researchers from ...
... shows only 7 percent of diabetics take the ... blood vessel problems. Researchers stressed continued negligence by ... retinopathy, neuropathy, nephropathy, coronary heart disease, stroke, and ... adults, ages 20 years or older, who had ...
... that causes excessive absence from work. Many doctors recommend an ... to normal activity levels. But many people with lower back ... new study suggests people with low back pain can benefit ... among the employees of an airline company in the Netherlands. ...
... 7 million patients suffering from chronic angina report limitations ... to three times more frequently than the general population. ... despite current treatments, such as myocardial revascularization -- a ... and is done largely to prevent angina -- and ...
... is an infection of the central nervous system caused ... the most common type of acquired epilepsy around the ... about 400,000 people. ,New research shows an antiparasitic ... a common parasite. ,Researchers speculated treatment with the ...
... study finds the abilities required for success in school ... workplace.// ,The idea that one’s cognitive abilities predict ... been controversial. Many people believe what is needed for ... academic success. Scientists from the University of Illinois tested ...
Cached Medicine News:Health News:Reducing Number Of Cigarettes Not Enough 2Health News:New Medication May Decrease The Frequency Of Angina Attacks 2
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... segment of the $13 billion global cardiac rhythm ... Kalorama Information.  Kalorama found that Medtronic, St. Jude ... Medical) command 80% of this market segment. The ... Management Device Markets , uses 2015 as a ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 ... CSL Behring its 2015 Corporate Leadership Award as ... science and improving the care of the bleeding disorders community.  ... and Managing Director, CSL Limited, during the NHF Annual Spring ... May 21. "The National Hemophilia Foundation is dedicated ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
... Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical ... Phase 3 bunionectomy study to evaluate the efficacy ... (bupivacaine extended-release liposome injection) is being presented in ... Annual Meeting of the Orthopaedic Research Society held ...
... As the first major medical center in North ... clinical practice groups, UT Southwestern Medical Center today applauded ... providers across the nation to embrace new health care ... goal of  "meaningful use" of electronic health records (EHR) ...
Cached Medicine Technology:Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting 2Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting 3UT Southwestern to Accelerate its Early Leadership in Using Electronic Health Records to Improve Patient Care 2
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: When high buckle is required. Overall length: 11.6 mm....
Asymmetrical concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: